Article Text
Therapeutics
Randomised controlled trial
Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy
Statistics from Altmetric.com
Footnotes
-
Competing interests JMF has received grants or research support from Daiichi Sankyo, Novartis and NIH and is a consultant or on a steering committee for Novartis, NIH, Daiichi Sankyo, Boehringer Ingleheim. He is also on the speakers bureau for Novartis, Daiichi Sankyo, Boehringer Ingleheim. SAN and PDL have no conflicting interests.